| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023935315 |
| P356 | DOI | 10.1186/S40478-016-0409-1 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/s40478-016-0409-1 |
| P932 | PMC publication ID | 5217191 |
| P698 | PubMed publication ID | 28057080 |
| P50 | author | Eliezer Masliah | Q28324209 |
| Edward Rockenstein | Q28324218 | ||
| Paula Desplats | Q57558150 | ||
| P2093 | author name string | Brian Spencer | |
| Elvira Valera | |||
| Michael Mante | |||
| Anthony Adame | |||
| Ivy Trinh | |||
| Jerel A Fields | |||
| P2860 | cites work | Mechanism of action of lenalidomide in hematological malignancies | Q21198872 |
| Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma | Q21285161 | ||
| Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1 | Q24296254 | ||
| Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration | Q24614960 | ||
| Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation | Q26771536 | ||
| Multiple system atrophy: a clinical and neuropathological perspective | Q26829838 | ||
| Analyzing real-time PCR data by the comparative C(T) method | Q28131831 | ||
| Cytokines and acute neurodegeneration | Q28190084 | ||
| Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy | Q28395248 | ||
| Widespread alterations of alpha-synuclein in multiple system atrophy | Q30444927 | ||
| ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo | Q30650119 | ||
| Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity | Q33280345 | ||
| Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis | Q33500473 | ||
| Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. | Q33649211 | ||
| Multiple system atrophy: a sporadic synucleinopathy | Q33750069 | ||
| α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy | Q33864597 | ||
| Tumor necrosis factor signaling. | Q34185821 | ||
| Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). | Q35064910 | ||
| A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies | Q35213879 | ||
| Neuropathological spectrum of synucleinopathies | Q35540178 | ||
| Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy | Q35544737 | ||
| Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease | Q35609611 | ||
| Myelin degeneration in multiple system atrophy detected by unique antibodies | Q35753409 | ||
| Thalidomide-derived immunomodulatory drugs as therapeutic agents | Q35967301 | ||
| Properties of thalidomide and its analogues: implications for anticancer therapy | Q36250757 | ||
| Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases | Q36330960 | ||
| Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice | Q36494725 | ||
| Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD. | Q36512589 | ||
| Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy | Q36672116 | ||
| Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. | Q36722978 | ||
| Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission | Q37117527 | ||
| Multiple system atrophy: a primary oligodendrogliopathy. | Q37282526 | ||
| Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in the brain. | Q37359456 | ||
| Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases | Q37949182 | ||
| Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma | Q38042444 | ||
| Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy | Q39405702 | ||
| A randomized clinical trial of lithium in multiple system atrophy | Q39561429 | ||
| The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. | Q39916867 | ||
| Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. | Q39980342 | ||
| Cellular pathology of multiple system atrophy: a review | Q40724377 | ||
| Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial | Q41603943 | ||
| Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein | Q41982270 | ||
| Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells | Q42140713 | ||
| The role of TLR4-mediated PTEN/PI3K/AKT/NF-κB signaling pathway in neuroinflammation in hippocampal neurons | Q42221514 | ||
| Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. | Q42486578 | ||
| Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters | Q42523541 | ||
| PI3K/Akt signaling pathway is required for neuroprotection of thalidomide on hypoxic-ischemic cortical neurons in vitro. | Q42939407 | ||
| Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). | Q43219125 | ||
| Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. | Q43935582 | ||
| Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways | Q45284571 | ||
| Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. | Q46970968 | ||
| Active immunotherapy facilitates Aβ plaque removal following through microglial activation without obvious T cells infiltrating the CNS. | Q48622959 | ||
| Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. | Q48786266 | ||
| TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. | Q54150165 | ||
| Microglial activation mediates neurodegeneration related to oligodendroglial α-synucleinopathy: Implications for multiple system atrophy | Q59273827 | ||
| Multiple system atrophy | Q73859080 | ||
| Effect of thalidomide on chemokine production by human microglia | Q74197639 | ||
| Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | Q77929272 | ||
| Neuropathology and pathophysiology of multiple system atrophy | Q84451489 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 1 | |
| P921 | main subject | Synuclein | Q24767155 |
| immunotherapy | Q1427096 | ||
| multiple system atrophy | Q1541975 | ||
| P304 | page(s) | 2 | |
| P577 | publication date | 2017-01-05 | |
| P1433 | published in | Acta Neuropathologica Communications | Q27724912 |
| P1476 | title | Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy | |
| P478 | volume | 5 |
| Q90003697 | Ageing as a risk factor for neurodegenerative disease |
| Q91762171 | Antibody-based immunotherapies for Parkinsonian syndromes |
| Q89520851 | Epigallocatechin gallate in multiple system atrophy (PROMESA) |
| Q90248470 | Immunotherapies in Huntington's disease and α-Synucleinopathies |
| Q58793525 | Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation |
| Q89868296 | Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions |
| Q49562668 | Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy. |
| Q46726761 | Multiple system atrophy: experimental models and reality |
| Q38751654 | Neuroinflammation as modifier of genetically caused neurological disorders of the central nervous system: Understanding pathogenesis and chances for treatment. |
| Q47663712 | Potential clinical utility of multiple system atrophy biomarkers |
| Q58722552 | Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model |
| Q64055695 | TNFα inhibitors as targets for protective therapies in MSA: a viewpoint |
| Q45940520 | The neuropathology of multiple system atrophy and its therapeutic implications. |
| Q91836016 | Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives |
| Q90615378 | alpha-Synuclein: a Modulator During Inflammatory CNS Demyelination |
Search more.